Post-traumatic stress disorder (PTSD) is a trauma- and stressor-related disorder that can develop after exposure to actual or threatened death, serious injury, or sexual violence. Although the initiating event is typically catastrophic or highly threatening, PTSD is best understood as a maladaptive neurobiological response to persistent cues of danger, combined with changes in cognitive appraisal, sleep regulation, and stress-hormone signaling. Clinically, PTSD is characterized by a triad of symptom clusters: intrusion symptoms (e.g., involuntary distressing memories, nightmares, dissociative reactions such as flashbacks), persistent avoidance of stimuli associated with the trauma (including avoidance of thoughts, feelings, people, places, or conversations), and negative alterations in cognition and mood (e.g., persistent negative beliefs, distorted blame of self or others, inability to experience positive emotions). A fourth cluster includes arousal and reactivity changes such as hypervigilance, exaggerated startle response, irritability or angry outbursts, concentration problems, and sleep disturbance.
Neurobiologically, PTSD involves dysregulation of fear conditioning and extinction learning. The amygdala is often hyperresponsive to threat cues, while top-down modulation from the prefrontal cortex—particularly regions implicated in executive control and contextual processing—may be impaired. The hippocampus, crucial for contextual memory and temporal ordering, can show functional and structural vulnerability, contributing to fragmented recall and overgeneralization of fear. At the systems level, chronic stress influences the hypothalamic-pituitary-adrenal (HPA) axis, with abnormal cortisol dynamics reported across studies; some individuals show hypocortisol patterns, while others demonstrate altered diurnal rhythms. Additionally, neuroinflammatory signaling and neurotransmitter imbalances have been implicated, including alterations in glutamatergic, GABAergic, and serotonergic pathways that affect threat processing and emotional regulation. These mechanisms help explain why PTSD symptoms are not only psychological but also involve measurable changes in attention, autonomic arousal, and sleep architecture.
Diagnostic evaluation is grounded in established criteria (e.g., DSM-5-TR), requiring symptom persistence for more than one month after the traumatic exposure and clinically significant distress or impairment in social, occupational, or other important functioning. Differential diagnosis is essential. Clinicians must rule out other conditions that can mimic PTSD, including acute stress disorder, major depressive disorder with prominent intrusive thoughts, generalized anxiety disorder, panic disorder, adjustment disorder, dissociative disorders, and substance/medication-induced disorders. Comorbidities are common: PTSD frequently co-occurs with depression, anxiety disorders, substance use disorders, traumatic brain injury, and chronic pain syndromes, which can worsen symptom severity and complicate treatment selection.
From a therapeutic perspective, evidence-based care typically combines trauma-focused psychotherapy with—when appropriate—pharmacotherapy. First-line psychotherapies include trauma-focused cognitive behavioral therapy (TF-CBT), prolonged exposure therapy, cognitive processing therapy (CPT), and eye movement desensitization and reprocessing (EMDR). These approaches aim to reduce the pathological fear structure by processing traumatic memories in a safe therapeutic context, correcting maladaptive appraisals (such as persistent self-blame), and strengthening extinction learning. For many patients, trauma-focused therapies can be delivered individually or, in some settings, via group formats; treatment planning should consider readiness, safety, and the patient’s current symptom profile.
Pharmacologic management is often used to target specific symptom domains (e.g., sleep, hyperarousal, mood, intrusive distress). Selective serotonin reuptake inhibitors (SSRIs) such as sertraline and paroxetine are commonly recommended, as they may reduce overall PTSD symptom burden. Other agents, including serotonin-norepinephrine reuptake inhibitors (SNRIs) and, in select cases, adjunctive treatments for insomnia or nightmares, may be considered. Medication selection should account for comorbid depression, anxiety, cardiovascular status, drug interactions, pregnancy considerations, and the individual’s response history. Importantly, medications generally do not replace trauma-focused psychotherapy; rather, combined strategies may improve outcomes when symptoms are severe or when psychotherapy is initially difficult to engage.
Complications of untreated PTSD include chronic functional impairment, increased risk of suicidal ideation, cardiovascular and metabolic effects associated with long-term stress physiology, and persistent interpersonal difficulties. Therefore, early recognition and coordinated care are crucial, especially after mass trauma or repeated exposures. For at-risk populations, clinicians should prioritize screening for PTSD and related conditions, offer psychoeducation on stress responses, and address barriers to treatment such as displacement, language access, stigma, and limited mental health infrastructure.
Supportive interventions also play a role: skills for grounding and emotional regulation, sleep hygiene, and strategies to reduce avoidance can help stabilize patients between therapy sessions. In crisis contexts, immediate safety planning and assessment for acute risk are essential. Over time, with effective trauma-focused treatment and consistent follow-up, many individuals experience substantial symptom reduction, improved sleep, and greater ability to engage with daily life.
Source: [Creator/Source] @ZelenskyyUa
Volodymyr Zelenskyy / Володимир Зеленський: Over this week, the Russians have launched more than 2,300 attack drones, nearly 1,560 guided aerial bombs, and 108 missiles of various types against our people. All these strikes were directed simply at ordinary civilian infrastructure – residential buildings and energy. #breaking
— @ZelenskyyUa May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
